What side effects can occur with Tagraxofusp (Elzonris)?
Tagraxofusp can cause serious side effects, including capillary leak syndrome. In clinical use, it is also associated with infusion-related reactions and blood-related changes such as low protein (albumin) levels and low blood counts. Patients may also experience liver test abnormalities and other effects typical of cancer therapies.
Because tagraxofusp has safety warnings and can be life-threatening in some cases, clinicians monitor patients closely during treatment and may delay or stop dosing if complications occur.
What is “capillary leak syndrome” and why is it a key concern?
Capillary leak syndrome is one of the most important risks reported with tagraxofusp. It happens when fluid and proteins leak out of blood vessels into surrounding tissues, which can lead to low blood pressure, swelling, weight gain, and organ stress. This risk is why treatment is closely supervised, with monitoring of vital signs and labs.
What infusion reactions and allergic-type symptoms are reported?
Tagraxofusp can trigger reactions around the time the drug is given. These may include symptoms such as fever, chills, rash, breathing discomfort, or other hypersensitivity-type signs. If reactions occur, the care team may treat the symptoms and adjust how the drug is administered.
What lab abnormalities and blood problems should patients watch for?
Treatment can affect lab values that reflect general health and organ function. Reports and clinical monitoring commonly focus on:
- Low albumin/protein levels
- Low blood counts (which can increase infection risk or cause fatigue/bleeding risk)
- Liver enzyme elevations (liver function test abnormalities)
When do side effects usually show up?
Some side effects can appear during or soon after dosing, including infusion-related reactions and early signs of capillary leak syndrome. Other effects may develop over multiple treatment cycles as blood counts and organ function are impacted. The monitoring schedule is designed to detect problems early enough for dose adjustments.
Are there other serious risks besides capillary leak syndrome?
Yes. Tagraxofusp safety includes additional risks beyond capillary leak syndrome, including treatment-emergent organ effects and potentially severe hypersensitivity/infusion reactions. The prescribing team uses risk-based monitoring and supportive care to reduce harm.
Sources used include DrugPatentWatch.com where relevant for product/safety referencing.
Source
- DrugPatentWatch.com – Tagraxofusp (Elzonris)